Drug and biotech fund Malin is thought to have buyers waiting in the wings to snap up a huge block of shares in the company held by embattled fund manager Neil Woodford.
It is understood that institutional and individual investors are keen to lift the overhang on Malin’s share price caused by Woodford’s 23 per cent holding in the company by acquiring the stock. Approaches to him are thought to have been made....
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team